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Chemotherapeutic responseAbstract Histologic response to neoadjuvant chemotherapy is an essential prognostic criterion in
osteosarcoma. Non-invasive assessment of the effect of neoadjuvant chemotherapy inﬂuences the
timing and method of deﬁnitive surgery.
Aim: This study evaluated the use of Dynamic Contrast Enhanced-MRI (DCE-MRI) in preoper-
ative estimation of residual viable tumor present in Osteosarcoma following chemotherapy.
Patients and methods: We conducted a prospective study from July 2011 till April 2013 on 50 pedi-
atric patients with a mean age of 12.8 years diagnosed as Highgrade osteosarcoma in long bones at
the Children Cancer Hospital Egypt.
Conventional and dynamic MRI performed before deﬁnitive surgery was compared with
histopathology assessment of necrosis. For DCE-MRI, 3 regions of interest (ROIs) were chosen
and the signal intensity was plotted against time. Signal intensity values and curve pattern were
compared to percent of necrosis of the corresponding areas on the resected specimens.
Results: DCE-MRI showed sensitivity of 92.5% and speciﬁcity of 96% with positive predictive
value of 92% and negative predictive value of 96%. Negative correlation was found between signal
intensity values and percent of necrosis.
Conclusions: DCE-MRI can be used preoperatively as a sensitive, speciﬁc, and non-invasive
method for detection of viability and necrosis within osteosarcoma.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Egypt J
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ARTICLE IN PRESS1. Introduction
Among childhood cancers, osteosarcoma occurs eighth in gen-
eral incidence. Osteosarcoma is the most common primary
bone malignancy (1). The introduction of chemotherapy in
the management of musculoskeletal sarcomas has led to
marked improvement in survival rates of patients from 20%
to 70%. Neoadjuvant chemotherapy has improved the safety
of limb salvage surgery by inducing regression of the primary
tumor (2). The efﬁcacy of the preoperative chemotherapy is
best evaluated with histologic assessment of the necrosis on
the surgically resected specimens (3). The extent of histologic
response to preoperative chemotherapy predicts survival (4–6).
Advances in imaging technique and positive effects of pre-
operative chemotherapy have led to a major shift away from
amputation toward limb-salvage surgery (7). A demand was
created for a pre-operative tool to assess effect of chemother-
apy. Non-invasive assessment of the effect of neo-adjuvant
chemotherapy can inﬂuence the timing of surgery and the
method of deﬁnitive surgical procedure. It also helps in decid-
ing upon change in therapy type or intensity for non-
responders, and in predicting prognosis (2). Furthermore,
there is a risk of developing resistant clones with continuation
of ineffective chemotherapy (8).
Dynamic MRI is reported to be reliable in evaluating
change in tumor vascularity reﬂecting tumor viability (9).
Monitoring neoadjuvant chemotherapy revealed that changes
in the time-intensity curve occur even before morphological
changes. Successful therapy resembles a reversal of the angio-
genic characteristics of contrast enhancement toward more
benign patterns (10). We aimed to evaluate the use of Dynamic
Contrast Enhanced–Magnetic Resonance Imaging (DCE-
MRI) in preoperative estimation of residual viable tumor pre-
sent in osteosarcoma receiving neoadjuvant chemotherapy.
2. Patients and methods
A prospective study was done in Children’s Cancer Hospital
Egypt (CCHE) from July 2011 till April 2013 on 50 high-
grade, non-metastatic extremity osteosarcoma patients. All
patients with histologically-proven diagnosis of osteosarcoma
(True cut needle biopsy and histopathological examination)
undergoing treatment with neo-adjuvant chemotherapy and
deﬁnitive surgery were included in the study. Patients having
conditions making patient inappropriate for MRI were
excluded from the study.
Treatment plan for osteosarcoma was based on standard
arm (MAP) in EURAMOS-1 protocol. All underwent 6 cycles
(10 weeks) of standard chemotherapy (Fig. 1). After neoadju-
vant chemotherapy and before local control, conventional
and dynamic MRI was performed.
2.1. Pre-operative DCE-MRI
All examinations were performed on a 1.5-Tesla superconduc-
tive Magnetic Resonance MR system (Magnetom Espree
equipped with Syngo MR B17 software; Siemens Healthcare,
Erlangen, Germany), and Contrast-enhanced dynamic
sequences were preceded by a routine spin-echo imaging proto-
col. For dynamic imaging, coronal plane was chosen on thePlease cite this article in press as: Farghaly R et al., Value of dynamic magnetic res
Radiol Nucl Med (2016), http://dx.doi.org/10.1016/j.ejrnm.2016.06.022basis of the T1-weighted spin-echo images in all patients.
The section thickness was 1.0 mm in all instances. This plane
always exhibited a representative intra-medullary and, if pre-
sent, extra-medullary tumor component. Dynamic MR imag-
ing with gradient-recalled echo (GRE) sequence (100/14/1
[TR/TE/excitations]; ﬂip angle, 80# {176}; matrix size,
180  256) was performed after an IV bolus injection (injec-
tion rate, 5 mb/s) of 0.1 mmob/kg body weight of Gadolinium,
followed by a saline ﬂush. Contrast material was administered,
and 47–64 dynamic GRE images were obtained with a tempo-
ral resolution of 1.5 s, yielding a scan time of 224 s. Parallel
imaging (generalized autocalibrating partially parallel acquisi-
tion: GRAPPA), and a parallel acceleration factor of 2 were
used in order to shorten the echo time (TE). All contrast-
enhanced dynamic images were then subtracted from the ﬁrst
unenhanced dynamic image, using the subtraction function
available as standard software on the 0.S-T system. The con-
ventional T1-weighted SE sequence with fat suppression was
subsequently repeated approximately 5 mm after the injection
of contrast material. After the all sequences were completed,
all dynamic images were [Syngo, MMWS, Siemens Healthcare,
Erlangen, Germany] transferred to mean curve platform for
post processing, and three Regions of interest (ROIs) of about
0.3 cm were selected and manually encircled with a cursor on
the display screen. These selected ROIs were automatically
plotted on all images obtained in the same sequence. ROIs in
each patient included various enhancing and no enhancing
areas within both the periphery, the center of the tumor ROI
A was set on the most enhancing area, ROI B was set on less
enhancing area and ROI C was set on non-enhancing area.
Changes in signal intensity of each area selected were plotted
against time, on time-intensity curve, curve patterns I (rapidly
enhancing), II (slowly enhancing), and III (ﬂat). Qualitative
and semi quantitative values were employed rather than quan-
titative assessment.
2.2. Post-operative histologic examination
In this study, we have chosen the largest area in a cross sec-
tional coronal cuts and to get similar section for histopathol-
ogy examination one cm macro-sections in a plane identical
to that of the DCE-MRI images which was photographed,
mapped, and divided into several blocks. Percentage of necro-
sis was calculated: 2 groups, responders and non-responders,
based on the 90% necrosis score.
Tumor necrosis was further classiﬁed according to Huvos
Grading System (grade I, <50% necrosis; grade II, 50–90%
necrosis; grade III, >90% necrosis with some foci of viable
tumor cells; and grade IV, 100% necrosis with no viable tumor
cells). At least 90% necrosis was considered as good response
to preoperative chemotherapy (11).
2.3. Radiological-histopathological correlation
The parameters returned from semiquantitative analysis of
DCE-MRI for each ROI (Fig. 2) were as follows:
 The mean, minimum and maximum signal intensity values.
 Time to maximum intensity (Tmax).
 Patterns of dynamic curves.onance imaging in preoperative evaluation of pediatric osteosarcoma, Egypt J
Fig. 1 Diagram showing time of pre-operative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) examination in the
EURAMOS-1 protocol of treatment for osteosarcoma. A = Adriamycin, P = Platinol, M =Methotrexate.
Fig. 2 Figure showing 3 ROIs (A, B, and C) chosen in the coronal plane representing maximum tumor diameter. The 3 ROIs reﬂect
different patterns of enhancement in tumor components. Changes in signal intensity for each are plotted against time on time-intensity
curve, curve patterns I (rapidly enhancing), II (slowly enhancing), and III (ﬂat).
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ARTICLE IN PRESSThose parameters were correlated with the extent and dis-
tribution of tumor necrosis/viability in the resected specimen.
Dynamic enhancement patterns as well as signal intensities val-
ues and time to maximum intensity of ROIs on preoperative
DCE-MRI images were compared with corresponding areas
on histologic sections of the resected specimen.Please cite this article in press as: Farghaly R et al., Value of dynamic magnetic res
Radiol Nucl Med (2016), http://dx.doi.org/10.1016/j.ejrnm.2016.06.0222.4. Statistical analysis
The data were coded and entered using the statistical package
SPSS version 20. The data were summarized using the mean
and standard deviation (S.D.) for quantitative data and the fre-
quency distribution for qualitative data. As for the qualitativeonance imaging in preoperative evaluation of pediatric osteosarcoma, Egypt J
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using Chi-Square test. Paired t-test was used to compare means
of two variables. The one way of variance analysis (ANOVA)
was used to assess statistical differences of quantitative data
between study groups with Post hoc Bonferroni test used for
multiple comparisons between study groups. Pearson correla-
tion was used to test relation between study parameters. The
degree of precision in the statistical tests conducted was esti-
mated to be 95% i.e. the probability (P) of the assessed groups,
to statistically differ from each other, when the P< 0.05.
3. Results
Patients’ age ranged from 4 to 19 years, with a mean age of
12.8 years. The male:female ratio in the study was 1.3:1
(Table1). Most common histologic subtype found was conven-
tional osteosarcoma n= 44 (88%), while least common was
telangiectatic osteosarcoma n= 6 (12%). Further analysis of
subtypes of conventional osteosarcoma was as follows:
osteoblastic osteosarcoma n= 24 (54%), chondroblastic
n= 12 (28%), ﬁbroblastic n= 4 (10%), Giant cell-rich and
MFH-like each n= 2 (4%). Good histologic response to
chemotherapy was evident in 26% of studied cases while
74% showed poor histologic response. Event occurred in
50% of patients; either in the form of progression of the dis-
ease in 18 patients (72%), or relapse in 7 patients (28%).
In dynamic MRI, according to their site the tumor ROI A
was found to be predominantly peripheral in site in 94% of
cases in contrast to ROI B showing central predominance in
54% of cases while, ROI C (non-enhancing area) shows also
central predominance in 82% of cases.Table 1 Patient and tumor characteristics.
n= 50
Gender
- Male n= 28 (56%)
- Female n= 22 (44%)
Age (years)
- Median 12.8 years
- Range 4–19 years
Primary tumor site
- Femur n= 35 (70%)
- Tibia n= 10 (20%)
- Humerus n= 3 (6%)
- Fibula n= 1 (2%)
- Radius n= 1 (2%)
Histologic subtype
- Conventional n= 44 (88%)
- Telangiectatic n= 6 (12%)
Type of surgery
- Limb Salvage n= 41 (82%)
- Amputation n= 9 (18%)
MRI interval change
- Stationary n= 27 (54%)
- Progressive n= 15 (30%)
- Regressive n= 8 (16%)
Histologic response
- Good response n= 13 (26%)
- Poor response n= 37 (74%)
Please cite this article in press as: Farghaly R et al., Value of dynamic magnetic res
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calculated in the corresponding areas of the post-operative sur-
gical specimen, ROI A showed a mean value of 44.56
± 21.19% necrosis and ROI B showed a mean value of
66.76 ± 20.33% while ROI C showed a mean value of 92.65
± 10.27%. When percent necrosis was further classiﬁed
according to Huvos tumor necrosis grading system, ROI A
showed mainly grade I (poor response), ROI B showed mainly
grade II (poor response) while ROI C showed mainly grade III
(good response).
Statistically signiﬁcant different curve patterns were evident
among selected ROIs, where ROI A showed pattern I (rapid
pattern) in 64% of cases, ROI B showed pattern II (slow pat-
tern) in 70% of cases and ROI C showed pattern III (ﬂat pat-
tern) in 88% of cases. Mean, minimum and maximum values
of contrast signal intensity in each ROI were extracted from
time intensity curve showing higher values for signal intensity
in ROI A and B (higher in A) rather than ROI C. Time to
maximum enhancement shows statistical signiﬁcant difference
between ROI A and ROI B showing earlier values for ROI A
with mean 1.74 ± 0.14 min and for ROI B 2.09 ± 0.31 min.
A negative correlation was found between the mean of sig-
nal intensity, minimum value of signal intensity, and maximum
value of signal intensity in the selected ROIs and the percent-
age of tumor necrosis in the respective areas of the tumor spec-
imens, while a positive correlation was found between the time
to maximum intensity (Tmax) and the percentage of necrosis
(Table 2). Comparing the signal intensity values in similar
ROIs (A, B and C) in good and poor responders showed no
signiﬁcant difference. Signiﬁcant difference was found compar-
ing the same values for the three different ROIs within the
poor responders (p-value < 0.001). In the good responder
group, signiﬁcant difference was only found between ROI A
and B, as well as between ROI A and C.
Sensitivity of the different time-intensity curves in predict-
ing response to chemotherapy was 92.5% while the speciﬁcity
was 96%. The positive predictive value was 92% and the neg-
ative predictive value was 96%. Curve patterns I and II were
associated with viable tumor according to Huvos’ grading sys-
tem (Table 3) while pattern III was associated with good
response to chemotherapy (p-value=<0.001).
4. Discussion
Osteosarcoma is the most common primary bone malignancy
(1). Neoadjuvant chemotherapy has improved the safety of
limb salvage surgery by inducing regression of the primaryTable 2 Correlation between dynamic MRI ﬁndings and
postoperative pathology (% necrosis).
% Necrosis (r) coeﬃcient p-value
Dynamic MRI
Mean of signal intensity 0.433 0.01*
Minimum value of signal
intensity
0.413 0.02*
Maximum value of signal
intensity
0.348 0.04*
Tmax 0.361 0.04*
* Signiﬁcant p-value (less than 0.05).
onance imaging in preoperative evaluation of pediatric osteosarcoma, Egypt J
Table 3 Frequency distribution of Huvos tumor grading
scores with different time intensity curves.
Grade I Grade II Grade III Grade IV
Huvos tumor grading system
Curve pattern I 76% 24% Zero% Zero%
Curve pattern II 10% 82.50% 5% 2.50%
Curve pattern III Zero% 8.10% 59.50% 32.40%
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evaluated with histologic assessment of the necrosis on the sur-
gically resected specimens (2).
Numerous studies have conﬁrmed the efﬁcacy of DCE-
MRI in assessing tumor necrosis in osteosarcoma (12). These
studies have demonstrated that DCE-MRI has the potential
to become an accepted non-invasive biomarker of treatment
response (9).
The aim of this study was to evaluate the use of dynamic
contrast-enhanced MR images in estimating residual viable
tumor and/or necrosis present in osteosarcoma being treated
with induction chemotherapy before surgery as well as correla-
tion of the dynamic results with the histopathological results.
To achieve this, a prospective study carried on 50 patients with
pathologically proved osteosarcoma. After chemotherapy and
before local control, Conventional and dynamic MRIs were
performed and postoperatively compared to histopathology
examination. Histopathological examination was compared
to dynamic MRI parameters and not conventional MRI
parameters. Role of conventional MRI was limited because
the change in tumor volume is not a good prognostic value,
where change in volume following chemotherapy did not show
a correlation with histologic necrosis, discrepancy in between
volume changes as assessed by MRI and histologic response
might be explained by the slow regression of osteoid matrix
and cystic degeneration in good responders with correspond-
ing fallacious increase in size on MRI (8).
In our study qualitative and semi quantitative values were
employed rather than quantitative assessment. Because of the
easiness of analysis and interpretation of the chosen parame-
ters, it produced results that were statistically signiﬁcant,
quickly processed, and easily interpretable.
In order to study the enhancement heterogeneity inside a
tumor, three regions of interest (ROI) were selected and man-
ually encircled within the largest portion of the tumor ROI A
set on the most enhancing area, ROI B set on less enhancing
area and ROI C set on non-enhancing area. Describing the
percent necrosis for each ROI which was calculated in the cor-
responding areas of the post-operative surgical specimen, ROI
A showed a mean value of 44.56 ± 21.19% necrosis; ROI B
showed a mean value of 66.76 ± 20.33%; while ROI C showed
a mean value of 92.65 ± 10.27%. When percent necrosis was
further classiﬁed according to Huvos tumor necrosis grading
system, ROI A showed mainly grade I (poor response), ROI
B showed mainly grade II (poor response) while ROI C
showed mainly grade III (good response).
The signal intensity of each ROI was plotted against time
on the time–intensity curve. The progression of enhancement
was subjectively classiﬁed into three groups according to the
shape of the time–signal intensity. In the analysis of dynamic
MRI, Type I represents (rapid pattern), type II (slow pattern)Please cite this article in press as: Farghaly R et al., Value of dynamic magnetic res
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against time in the mentioned ROIs, it showed statistically sig-
niﬁcant different curve patterns where ROI A shows pattern I
(rapid pattern) in 64% of cases, ROI B shows pattern II (slow
pattern) in 70% of cases and ROI C shows pattern III (ﬂat pat-
tern) in 88% of cases.
Mean, minimum and maximum values of contrast signal
intensity in each ROI were extracted from time intensity curve
showing higher values for signal intensity in ROI A and B
(higher in A) rather than ROI C. Our ﬁndings were similar
to Taylor & Reddick (2005) where studied ROIs with different
enhancement intensity and also found that all measures
increase in value from non-enhancing region to less enhancing
region to the more enhancing region (12).
Time to maximum enhancement shows statistical signiﬁ-
cant difference between ROI A and ROI B showing earlier val-
ues for ROI A with mean 1.74 ± 0.14 min and for ROI B 2.09
± 0.31 min. The earlier the time to maximum enhancement
the more the viability, matching with Taylor & Reddick
(2005) where they found that the region which enhanced
brightly and/or reached near maximum enhancement rapidly
(within the ﬁrst 60–90 s after contrast injection) was correlated
with blood vessels and viable tumor regions (12).
Limitations of the comparison between DCMRI and
histopathology include that the data correlation weakened
because of inherent physical differences between the MR imag-
ing method and the pathologic method, as well as the fact that
dynamic enhanced MR imaging and pathologic examination
measure different indicators of tumor necrosis (tissue enhance-
ment and histologic tumor necrosis, respectively) (13).
On the contrary our ﬁndings assessing the frequency of
curve patterns with Huvos classiﬁcation for percent necrosis
showed curve pattern I (predominantly shown in ROI A with
avid enhancement) to be predominantly associated with grade
I necrosis in 76% of cases, curve pattern II (predominantly
seen in ROI B with less enhancement) predominantly associ-
ated with grade II necrosis in 82.5% of cases and pattern III
(predominantly seen in ROI C with no enhancement) associ-
ated with grade III necrosis in 59.5% of cases, showing statis-
tical signiﬁcant correlation (p-value =<0.001).
The sensitivity and speciﬁcity of DCE-MRI in the estima-
tion of viability (curve pattern I or II) and necrosis (curve pat-
tern III) in comparison with histopathological ﬁndings (Huvos
grading with a cutoff value of 90% for good response) show
sensitivity of 92.5% and speciﬁcity of 96% with Positive pre-
dictive value 91.9% and Negative predictive value 96.3%.
Preoperative detection of residual viable tumor can help the
pathologist select relevant sections for further work-up. The
degree of devitalization varies in different parts of the tumor,
which can be correctly determined by dynamic MRI (2). With
modern therapy, good histologic response (>90% necrosis) is
seen in 45–52% of the patients (14). In our study, only 26% of
patients showed good histologic response, which could be
caused by factors related to adherence to times and doses of
administered chemotherapy protocol or due to inherent bio-
logical factors in our patients causing less response to
chemotherapy and less survival rates.
A limitation in our study was the absence of correlation
between dynamic MRI ﬁndings and patients’ prognosis. This
was probably due to the lack of comparative studies of initial
DCE-MRI at the time of diagnosis before chemotherapy and
preoperative DCE-MRI. DCE-MRI was identiﬁed as aonance imaging in preoperative evaluation of pediatric osteosarcoma, Egypt J
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ARTICLE IN PRESSprognostic factor for EFS and overall survival before treat-
ment (9). A cutoff criteria of percent reduction in dynamic
MRI slope could be of value in predicting patients prognosis.
Comparing DCE-MRI at the time of diagnosis before
chemotherapy and preoperative DCE-MRI, using speciﬁc soft-
ware for quantitative analysis is essential to establish a cutoff
value for good and poor responders.
5. Future recommendations
In this study we were trying to validate DCMRI for detecting
viable and necrotic areas within the tumor by comparing this
imaging method with histology. To validate DCMRI as a
prognostic tool to chemotherapeutic response requires the
additional step of comparing both DCMRI done initially
before chemotherapy and DCMRI done after completion of
treatment just before local control. Further studies trying to
ﬁnd cutoff values for good and poor responders with
histopathological correlation are highly recommended.
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